Vyne Therapeutics Stock Forward View
| VYNE Stock | USD 0.57 0.01 1.79% |
Vyne Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Vyne Therapeutics stock prices and determine the direction of Vyne Therapeutics's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Vyne Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
The RSI of Vyne Therapeutics' stock price is about 62. This entails that the stock is rather overbought by investors at the present time. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Vyne, making its price go up or down. Momentum 62
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.15) | EPS Estimate Current Year (0.89) | EPS Estimate Next Year (1.10) | Wall Street Target Price 2 | EPS Estimate Current Quarter (0.14) |
Using Vyne Therapeutics hype-based prediction, you can estimate the value of Vyne Therapeutics from the perspective of Vyne Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Vyne Therapeutics on the next trading day is expected to be 0.62 with a mean absolute deviation of 0.02 and the sum of the absolute errors of 1.47. Vyne Therapeutics after-hype prediction price | USD 0.57 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Vyne Therapeutics to cross-verify your projections. Vyne Therapeutics Additional Predictive Modules
Most predictive techniques to examine Vyne price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Vyne using various technical indicators. When you analyze Vyne charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Vyne Therapeutics Cash Forecast
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Vyne Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2016-12-31 | Previous Quarter 22 M | Current Value 19.3 M | Quarterly Volatility 28.1 M |
Vyne Therapeutics Naive Prediction Price Forecast For the 5th of February
Given 90 days horizon, the Naive Prediction forecasted value of Vyne Therapeutics on the next trading day is expected to be 0.62 with a mean absolute deviation of 0.02, mean absolute percentage error of 0, and the sum of the absolute errors of 1.47.Please note that although there have been many attempts to predict Vyne Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Vyne Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Vyne Therapeutics Stock Forecast Pattern
| Backtest Vyne Therapeutics | Vyne Therapeutics Price Prediction | Research Analysis |
Vyne Therapeutics Forecasted Value
In the context of forecasting Vyne Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Vyne Therapeutics' downside and upside margins for the forecasting period are 0.01 and 7.74, respectively. We have considered Vyne Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Vyne Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Vyne Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.2143 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0237 |
| MAPE | Mean absolute percentage error | 0.0497 |
| SAE | Sum of the absolute errors | 1.4713 |
Predictive Modules for Vyne Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vyne Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vyne Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Vyne Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Vyne Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Vyne Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Vyne Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Vyne Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Vyne Therapeutics' historical news coverage. Vyne Therapeutics' after-hype downside and upside margins for the prediction period are 0.03 and 7.63, respectively. We have considered Vyne Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Vyne Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Vyne Therapeutics is based on 3 months time horizon.
Vyne Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Vyne Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vyne Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Vyne Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.02 | 7.12 | 0.01 | 0.13 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.57 | 0.57 | 0.00 |
|
Vyne Therapeutics Hype Timeline
Vyne Therapeutics is at this time traded for 0.57. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.13. Vyne is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is at this time at 1.02%. %. The volatility of related hype on Vyne Therapeutics is about 5788.62%, with the expected price after the next announcement by competition of 0.44. About 15.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.59. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vyne Therapeutics recorded a loss per share of 0.79. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 13th of February 2023. Given the investment horizon of 90 days the next estimated press release will be in about 9 days. Check out Historical Fundamental Analysis of Vyne Therapeutics to cross-verify your projections.Vyne Therapeutics Related Hype Analysis
Having access to credible news sources related to Vyne Therapeutics' direct competition is more important than ever and may enhance your ability to predict Vyne Therapeutics' future price movements. Getting to know how Vyne Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Vyne Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AIM | AIM ImmunoTech | 0.05 | 9 per month | 0.00 | (0.17) | 7.69 | (10.32) | 29.72 | |
| KALA | Kala Pharmaceuticals | (0.36) | 6 per month | 0.00 | (0.05) | 12.28 | (11.32) | 59.48 | |
| KTTA | Pasithea Therapeutics Corp | 0.01 | 10 per month | 7.54 | 0.07 | 16.67 | (12.50) | 137.41 | |
| SNGX | Soligenix | (0.03) | 10 per month | 0.00 | (0.06) | 7.03 | (6.52) | 30.10 | |
| TCRT | Alaunos Therapeutics | (0.18) | 7 per month | 5.49 | 0.01 | 9.61 | (10.55) | 24.31 | |
| BCLI | Brainstorm Cell Therapeutics | (0.01) | 6 per month | 0.00 | (0.04) | 9.09 | (6.67) | 24.01 | |
| QNRX | Quoin Pharmaceuticals Ltd | (0.66) | 12 per month | 0.00 | (0.02) | 18.69 | (11.19) | 77.47 | |
| ENSC | Ensysce Biosciences | 0.03 | 10 per month | 0.00 | (0.34) | 5.94 | (11.25) | 23.86 | |
| XTLB | XTL Biopharmaceuticals Ltd | (0.03) | 10 per month | 0.00 | (0.03) | 7.79 | (10.38) | 69.50 | |
| MTNB | Matinas BioPharma Holdings | (0.05) | 7 per month | 0.00 | (0.14) | 11.67 | (10.67) | 39.32 |
Other Forecasting Options for Vyne Therapeutics
For every potential investor in Vyne, whether a beginner or expert, Vyne Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Vyne Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Vyne. Basic forecasting techniques help filter out the noise by identifying Vyne Therapeutics' price trends.Vyne Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vyne Therapeutics stock to make a market-neutral strategy. Peer analysis of Vyne Therapeutics could also be used in its relative valuation, which is a method of valuing Vyne Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Vyne Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Vyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vyne Therapeutics shares will generate the highest return on investment. By undertsting and applying Vyne Therapeutics stock market strength indicators, traders can identify Vyne Therapeutics entry and exit signals to maximize returns.
Vyne Therapeutics Risk Indicators
The analysis of Vyne Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Vyne Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting vyne stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.2 | |||
| Semi Deviation | 2.35 | |||
| Standard Deviation | 6.89 | |||
| Variance | 47.54 | |||
| Downside Variance | 14.28 | |||
| Semi Variance | 5.51 | |||
| Expected Short fall | (5.53) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Vyne Therapeutics
The number of cover stories for Vyne Therapeutics depends on current market conditions and Vyne Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Vyne Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Vyne Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Vyne Therapeutics Short Properties
Vyne Therapeutics' future price predictability will typically decrease when Vyne Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Vyne Therapeutics often depends not only on the future outlook of the potential Vyne Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vyne Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 42.6 M | |
| Cash And Short Term Investments | 61.5 M |
Check out Historical Fundamental Analysis of Vyne Therapeutics to cross-verify your projections. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could Vyne diversify its offerings? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Vyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth 0.397 | Return On Assets | Return On Equity |
Understanding Vyne Therapeutics requires distinguishing between market price and book value, where the latter reflects Vyne's accounting equity. The concept of intrinsic value - what Vyne Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Vyne Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vyne Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.